← Research library

Vesugen — originating-institute clinical report

Comparison in people

What was studied
40 patients with atherosclerosis, ages 54–77. Vesugen plus conventional care: 25. Conventional care: 15. Enrollment ran from November 2005 to February 2006.
Main finding
In a 40-patient report, mean post-treatment total cholesterol was 6.4 mmol/L with Vesugen plus conventional care and 7.0 mmol/L with conventional care alone. The report gives one shared baseline column.

Total cholesterol, mmol/L · 8.2 ± 0.3 before treatment. 6.4 ± 0.3 with Vesugen plus usual care and 7.0 ± 0.2 with usual care at follow-up. · p<0.05 vs the single reported baseline value for both post-treatment columns. No between-group test is shown.

Reported findings and study design

Comparative institutional report from St. Petersburg. Investigators assessed symptoms and used blood lipid testing, routine blood and urine tests, and coagulation measures.

Population or model 40 patients with atherosclerosis, ages 54–77. Vesugen plus conventional care: 25. Conventional care: 15. Enrollment ran from November 2005 to February 2006.

Dose, route and schedule

In the study, participants took 1–2 oral capsules 2–3 times daily, 10–15 minutes before meals, over 10–15 days. The clinical methods do not specify the mass of peptide per capsule.

Protocol source ↗ · Originating institute report, clinical methods and Tables 1–2

Results · Originating institute report, clinical methods and Tables 1–2
MeasureResultComparison, timing and statistics
Total cholesterol, mmol/L8.2 ± 0.3 before treatment. 6.4 ± 0.3 with Vesugen plus usual care and 7.0 ± 0.2 with usual care at follow-up.p<0.05 vs the single reported baseline value for both post-treatment columns. No between-group test is shown.
Very-low-density lipoproteins, mmol/L1.23 ± 0.05 at baseline. 0.96 ± 0.05 with Vesugen plus usual care and 1.08 ± 0.04 with usual care at follow-up.
Triglycerides, mmol/L4.5 ± 0.2 at baseline. 4.1 ± 0.2 with Vesugen plus usual care and 4.2 ± 0.7 with usual care at follow-up.

Table 2 gives a single pretreatment column. The report does not document blinded allocation or a between-group efficacy estimate, and it provides no long-term vascular outcomes.

Source for these results ↗ · Reviewed 2026-11-16

Study limitations and source details

Study limitations

  • Commercially distributed institute report; independent peer review, randomization and blinding not established.
  • Product composition is not independently characterized here; do not equate a marketed formulation with a purified experimental sequence.
  • Reported absence of harms does not establish safety.

Source details

Institute report / commercial reproduction

Originating institute report, clinical methods and Tables 1–2

Sources checked

Citation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Human comparative studyFull text available

Originating institute; report reproduced in commercial collection. Vesugen — originating-institute clinical report Reports on clinical studies of CYTOMAX and CYTOGEN products; PDF page 101

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards